Pharmaceutical company SANTO gains Good Manufacturing Practice (GMP) accreditation, expanding into fresh markets
👀 So, the SANTO factory in Kazakhstan just got the green light to join the international pharmaceutical scene with their antidiabetic meds, sitagliptin and dapagliflozin!
But let's not get too excited without knowing the deetz, okay? Here's what we do know:
Sitagliptin is part of that trusty DPP-4 inhibitor crew, keeping those blood sugar levels in check. By blocking the DPP-4 enzyme, sitagliptin lets our bodies generate more insulin, and we all need that sweet stuff to keep our sugars from going rogue. And did you hear? DPP-4 inhibitors like sitagliptin have been approved by regulatory bods worldwide for their safety and efficacy! Sounds like the real deal to me.
Now, let's talk dapagliflozin. This little pill is a SGLT-2 inhibitor, and it works by letting extra glucose out of our bodies through our pee. Ta-da! Less sugar floating around equals lower blood sugar levels. But remember, while SGLT-2 inhibitors can be super effective, they do come with some risks, such as genital infections and diabetic ketoacidosis. So, as always, talk to your doc before taking any new meds.
Now, back to SANTO. To get the European Union's stamp of approval, they whipped their production processes into shape, bringing them in line with the Good Manufacturing Practice (GMP) standard. This global standard ensures that quality-sensitive goods like meds and foods are made with top-notch quality and safety.
To hit this standard, SANTO spruced up their tablet-making game by introducing new equipment, implementing serialization systems, and automating secondary packaging processes. They also instilled a "quality mindset" among their employees, making everyone feel accountable for turning out winning meds.
With the GMP certificate under their belts, SANTO is ready to conquer the global market. They're currently offering over 280 meds for treating a variety of diseases, and they're not stopping there! Keep an eye on 'em, and we might just see them pop up in your local pharmacy one of these days!
- I am encouraged by the news that SANTO's factory in Kazakhstan is joining the international pharmaceutical scene with their antidiabetic meds, sitagliptin and dapagliflozin.
- The GMP certificate that SANTO has recently obtained is a testament to their commitment to quality and safety, as they have whipped their production processes into shape to meet the Good Manufacturing Practice (GMP) standard.
- To ensure the success of SANTO's products, they have introduced new equipment, implemented serialization systems, and automated secondary packaging processes, creating a "quality mindset" among their employees.
- With their focus on science and health-and-wellness, SANTO is currently offering over 280 medications for treating a variety of diseases, and their global presence could soon extend to my local pharmacy.
